okay, here’s a comprehensive article based on ⁣the provided CNBC excerpt, ‍expanded with semantic ⁤branching, E-E-A-T ⁤principles, and ⁢the required components. ⁤it’s designed to be Google News-friendly and informative.⁢ I’ve aimed for a tone that’s confident, fair, and‍ avoids sensationalism.

Trump Strikes Deals with Eli Lilly & Novo Nordisk to Lower Weight Loss ⁢Drug⁤ Prices: what You Need to Know

Washington D.C. ⁣- In a move poised to considerably⁣ impact healthcare access, President Donald⁣ Trump announced landmark agreements on Thursday, November 6, 2025, with pharmaceutical giants Eli Lilly ⁢and Novo Nordisk. These ‍deals aim to drastically reduce ⁤the⁣ out-of-pocket costs of popular and forthcoming weight loss drugs, possibly opening treatment to millions more Americans. The⁣ agreements leverage the administration’s “most favored nation” policy, capping monthly costs ⁢for patients ⁢based on ⁤dosage and insurance coverage.

What Happened? The ⁢Core of the Agreements

The core of the agreements centers around capping the monthly out-of-pocket costs for GLP-1 receptor agonists – a ⁢class ⁣of drugs initially developed for diabetes ⁣but ⁤demonstrating important efficacy in weight loss. Currently, drugs like Eli Lilly’s Zepbound and Novo Nordisk’s ⁢Wegovy carry list prices exceeding $1,000 per ⁤month, effectively excluding⁣ many patients.

Under the new agreements:

* Price Caps: Monthly costs will range ‍from $50 to $350, depending on dosage and insurance coverage.
* Medicare Coverage: For the first time, ‍Medicare⁤ will cover GLP-1 ⁤drugs specifically for obesity ‍starting in mid-2026. Previously,coverage was⁤ limited to conditions ⁣like diabetes and cardiovascular risk reduction (in Wegovy’s case).
* “Most Favored Nation” Policy: The ⁤deals are structured under ⁣the administration’s “most favored⁤ nation” policy, which⁣ aims to ensure Americans⁣ don’t pay more for prescription drugs than citizens of other developed ⁣countries.
* company Commitments: Both⁣ Eli Lilly ⁤and Novo Nordisk have already ⁤introduced lower-cost options ⁢for cash-paying customers, but these⁢ agreements expand ⁢access beyond direct-to-consumer programs.

What Does This Mean? ⁢ A ⁢Deep Dive into the Implications

This announcement represents a significant shift in the landscape of obesity treatment.The high cost of GLP-1s ‍has been a major barrier to access,despite their proven effectiveness. Lowering these costs has ⁤several potential ramifications:

* ⁤ Increased Access: Millions more americans,⁣ particularly seniors on Medicare, will be able to afford these medications.
* ⁣ Public Health Impact: obesity ⁢is a major risk factor for numerous chronic diseases, including heart disease,⁣ stroke, ⁢type 2 diabetes, and‍ certain cancers. Widespread ⁤access to effective weight loss treatments could lead to⁢ substantial improvements in public health.
* ⁤ Healthcare⁣ cost Reduction: While the initial cost of the drugs remains substantial, preventing or delaying⁤ the onset of obesity-related diseases could ultimately⁤ reduce ‍overall healthcare spending.
* Pressure on ⁢Private Insurers: ⁢ With‍ Medicare now covering these drugs for obesity, private insurers are likely to follow suit, further expanding access.
* Pharmaceutical Industry Response: The⁣ agreements could set a precedent for future negotiations with pharmaceutical companies, potentially⁢ leading to⁢ lower drug⁣ prices across the board.